Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
77.96 USD +0.79% Intraday chart for Hologic, Inc. +3.23% +9.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Watching for Indications of a Changed Fed Outlook; Plus, How One Company Avoided Mass Layoffs DJ
Hologic Insider Sold Shares Worth $1,241,296, According to a Recent SEC Filing MT
Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test CI
Transcript : Hologic, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 08:40 AM
FDA warns of potential risk from Hologic's devices implanted in soft tissue RE
FDA warns of potential risk of complications with use of Hologic's devices RE
UBS Adjusts Hologic's Price Target to $79 From $78, Maintains Neutral Rating MT
Needham Adjusts Price Target on Hologic to $90 From $83, Maintains Buy Rating MT
Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on September 23, 2022. CI
Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on November 9, 2023. CI
Hologic Gets FDA Clearance For Cancer-Cell Diagnostic System DJ
Hologic, Inc. Announces First and Only FDA-Cleared Digital Cytology System ? Genius? Digital Diagnostics System CI
Hologic upgrades annual sales forecast on strong demand for its breast health products RE
Hologic Fiscal Q1 Adjusted Earnings, Revenue Decline; Q2, Fiscal 2024 Outlooks Issued MT
Transcript : Hologic, Inc., Q1 2024 Earnings Call, Feb 01, 2024
(HOLX) HOLOGIC Forecasts Q2 EPS Range $0.95 - $1.00 MT
(HOLX) HOLOGIC Forecasts Fiscal Year 2024 EPS Range $3.97 - $4.12 MT
Earnings Flash (HOLX) HOLOGIC Posts Q1 Revenue $1.01B, vs. Street Est of $983.6M MT
Earnings Flash (HOLX) HOLOGIC Reports Q1 EPS $0.98, vs. Street Est of $0.95 MT
Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024 CI
Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023 CI
Hologic, Inc. Reports Earnings Results for the First Quarter Ended December 30, 2023 CI
Fed shuffles rate diary, BoE and Apple awaited RE
Hologic Insider Sold Shares Worth $1,120,500, According to a Recent SEC Filing MT
BofA Securities Raises Price Target on Hologic to $80 From $75, Maintains Neutral Rating MT
Chart Hologic, Inc.
More charts
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
77.96 USD
Average target price
82.67 USD
Spread / Average Target
+6.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Hologic, Inc. - Nasdaq
  4. News Hologic, Inc.
  5. Hologic : Earnings Flash (HOLX) HOLOGIC Posts Q3 Revenue $1.17B, vs. Street Est of $1.039B